The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
Open accessAbstract
BACKGROUND: Combined androgen blockade for the treatment of metastatic prostate cancer consists of an antiandrogen drug plus castration. In a previous trial, we found that adding the antiandrogen flutamide to leuprolide acetate (a synthetic gonadotropin-releasing hormone that results in medical ablation of testicular function) significantly improved survival as compared with that achieved with placebo plus leuprolide acetate. In the current trial, we compared flutamide plus bilateral orchiectomy with placebo plus orchiectomy. METHODS: We randomly assigned patients who had never received antiandrogen therapy and who had distant metastases from adenocarcinoma of the prostate to treatment with bilateral orchiectomy and either flutamide or placebo. Patients were stratified according to the extent of disease and according to performance status. RESULTS: Of the 1387 patients who were enrolled in the trial, 700 were randomly assigned to the flutamide group and 687 to the placebo group. Overall, the incidence of toxic effects was minimal; the only notable differences between the groups were the greater rates of diarrhea and anemia with flutamide. There was no significant difference between the two groups in overall survival (P=0.14). The estimated risk of death (hazard ratio) for flutamide as compared with placebo was 0.91 (90 percent confidence interval, 0.81 to 1.01). Flutamide was not associated with enhanced benefit in patients with minimal disease. CONCLUSIONS: The addition of flutamide to bilateral orchiectomy does not result in a clinically meaningful improvement in survival among patients with metastatic prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The first generation of true antiandrogen molecules used in the clinic, including bicalutamide (Casodex) and flutamide, aimed at inhibiting AR transcriptional activity by specifically targeting ligand binding to the AR (8,9).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huggins, C., & Hodges, C. V. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(05)64820-3 · Cited by 3,856
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Parker, S. L., Tong, T., Bolden, S., & Wingo, P. A. (1997) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.47.1.5 · Cited by 2,000
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Self-citationLeuprolide versus Diethylstilbestrol for Metastatic Prostate Cancer
The Leuprolide Study Group (1984) · New England Journal of Medicine · doi:10.1056/nejm198411153112004 · Cited by 622
Byar, D. P. (1973) · Cancer · doi:10.1002/1097-0142(197311)32:5 · Cited by 595
Designs for group sequential tests
Fleming, T. R., Harrington, D. P., & O’Brien, P. C. (1984) · Controlled Clinical Trials · doi:10.1016/s0197-2456(84)80014-8 · Cited by 354
Prostate Cancer Trialists' Collaborative Group (1995) · The Lancet · doi:10.1016/s0140-6736(95)92163-x · Cited by 320
Rubinstein, L., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 270
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
Eisenberger, M. A., Simon, R., O'Dwyer, P. J., Wittes, R. E., & Friedman, M. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.6.827 · Cited by 265
Self-citationGoserelin acetate and flutamide versus bilateral orchiectomy: a phase III eortc trial (30853)
Denis, L., Moura, J. L. C. D., Bono, A. V., Sylvester, R. J., Whelan, P., Newling, D., & Depauw, M. (1993) · Urology · doi:10.1016/0090-4295(93)90634-m · Cited by 257
Dalesio, O., VANTINTEREN, H., Denis, L., Schröder, F. H., Blumenstein, B. A., Godwin, J., & Peto, R. (1995) · The Lancet · Cited by 229
Self-citationKuhn, J., Billebaud, T., Navratil, H., Moulonguet, A., Fiet, J., Grise, P., Louis, J. F., Costa, P., Husson, J., Dahan, R., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210701 · Cited by 209
Caubet, J.-F., Tosteson, T. D., Dong, E. W., Naylon, E. M., Whiting, G. W., Ernstoff, M. S., & Ross, S. D. (1997) · Urology · doi:10.1016/s0090-4295(96)00325-1 · Cited by 203
Janknegt, R. A., Abbou, C. C., Bartoletti, R., Bernstein-Hahn, L., Bracken, B. R., Brisset, J. M., Silva, F. C. D., CHISHOLM, G. D., Crawford, E. D., Debruyne, F. M. J., et al. (1993) · The Journal of Urology · doi:10.1016/s0022-5347(17)36003-2 · Cited by 181
Self-citationPeeling, W. B. (1989) · Urology · doi:10.1016/0090-4295(89)90106-4 · Cited by 179
Labrie, F., Dupont, A., Bèlanger, A., Giguère, M., Lacoursiere, Y., Emond, J., Monfette, G., & Bergeron, V. (1985) · Journal of Steroid Biochemistry · doi:10.1016/s0022-4731(85)80024-8 · Cited by 152
Mechanism of action and pure antiandrogenic properties of flutamide
Labrie, F. (1993) · Cancer · doi:10.1002/1097-0142(19931215)72:12+ · Cited by 140
Self-citationEisenberger, M., Crawford, E. D., Wolf, M. C., Blumenstein, B. A., McLeod, D. G., Benson, R., Dorr, F. A., Benson, M., & Spaulding, J. T. (1994) · PubMed · Cited by 90
Self-citationEisenberger, M. A., O'Dwyer, P. J., & Friedman, M. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.3.414 · Cited by 69
Self-citationMedical Castration of Males with Megestrol Acetate and Small Doses of Diethylstilbestrol*
Geller, J., ALBERT, J. D., Yen, S. S. C., Geller, S., & Loza, D. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-52-3-576 · Cited by 53
Labrie, F., Veilleux, R., & Fournier, A. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.14.1138 · Cited by 53
Overview analysis issues using combined androgen deprivation overview analysis as an example
Blumenstein, B. A. (1995) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/1078-1439(95)00026-e · Cited by 8
Self-citation
Research works printed but not linked: 3
- Huggins C, 1941, Cancer Res, 1, 293
- 10.1002/1097-0142(19931215)72:12+<3834::AID-CNCR2820721714>3.0.CO;2-Z · DOI
- Eisenberger MA, 1994, Semin Oncol, 21, 613
Cited by
Sorted by citations
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Petrylak, D. P., Tangen, C. M., Hussain, M., Lara, P. N., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D. L., Moinpour, C. M., Kohli, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041318 · Cited by 3,665
Self-citationNatural History of Progression After PSA Elevation Following Radical Prostatectomy
Pound, C. R. (1999) · JAMA · doi:10.1001/jama.281.17.1591 · Cited by 3,077
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,958
Self-citationThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326
Metadata
- Authors
- Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Bueschen, A. J., & Lowe, B. A.
- Affiliations
- Johns Hopkins Hospital (US)
- SWOG Cancer Research Network (US)
- University of Colorado Denver (US)
- Walter Reed National Military Medical Center (US)
- University of Wisconsin–Madison (US)
- University of Oklahoma Health Sciences Center (US)
- University of Alabama at Birmingham (US)
- Oregon Health & Science University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-10-08
- Volume
- 339
- Issue
- 15
- Pages
- 1036-1042
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003985632
- Cited by
- 859
- References
- 25
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 8 · 2023: 12 · 2022: 20 · 2021: 15 · 2020: 21 · 2019: 26 · 2018: 25 · 2017: 23 · 2016: 34 · 2015: 52 · 2014: 49 · 2013: 51 · 2012: 37
- FWCI
- 37.16
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (2u10ca038926-25)
- National Cancer Institute (CA-32102, CA 42777, U10CA032102, U10CA042777, CA 38926)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- metastatic prostate cancer, bilateral orchiectomy, flutamide, combined androgen blockade, leuprolide, antiandrogen therapy, overall survival, adverse effects, anemia, diarrhea
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Androgen Antagonists, Bone Neoplasms, Combined Modality Therapy, Double-Blind Method, Flutamide, Humans, Male, Middle Aged, Orchiectomy, Prostatic Neoplasms, Soft Tissue Neoplasms, Survival Analysis, Prostate-Specific Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
